Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 16/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17134706 | 0.94 | FASN (0.42) | FASNMAP3K12CACNA1B | |
| SCHEMBL17134601 | 0.90 | FASN (0.43) | FASNMAP3K12DHODHMAPTSMN1; SMN2 | |
| SCHEMBL17135184 | 0.88 | FASN (0.42) | FASNMAP3K12DHODHMAPTSMN1; SMN2 | |
| SCHEMBL17135104 | 0.87 | FASN (0.43) | FASNMAPTSMN1; SMN2 | |
| SCHEMBL17134928 | 0.87 | FASN (0.41) | FASNMAPTSMN1; SMN2 | |
| SCHEMBL17134876 | 0.86 | FASN (0.42) | FASNMAPT | |
| SCHEMBL17134514 | 0.84 | FASN (0.42) | FASNMAPTSMN1; SMN2 | |
| SCHEMBL17135055 | 0.84 | FASN (0.40) | FASNMAPT | |
| SCHEMBL17134578 | 0.84 | PRSS12 (0.40) | FASNDHODHSMN1; SMN2 | |
| SCHEMBL17135189 | 0.84 | FASN (0.39) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2927214-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9701689-B2 | Substituted pyridines and pyridazines as CCR10 receptor inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| CN-104995173-A | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO LTD | 2015-10-21 | — | — | CN | disclosed |
| EP-2927214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | ARG1, H1-0, TYR | FASN 4391/4885MAP3K12 1971/4885CACNA1B 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.